- Home
- TARS
as 10-28-2025 4:00pm EST
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.
Upcoming Earnings Alert:
Get ready for potential market movements as Tarsus Pharmaceuticals Inc. TARS prepares to release earnings report on 04 Nov 2025.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | IRVINE |
| Market Cap: | 2.8B | IPO Year: | 2020 |
| Target Price: | $69.43 | AVG Volume (30 days): | 613.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.31 | EPS Growth: | N/A |
| 52 Week Low/High: | $38.51 - $76.81 | Next Earning Date: | 11-04-2025 |
| Revenue: | $295,521,000 | Revenue Growth: | 254.45% |
| Revenue Growth (this year): | 139.46% | Revenue Growth (next year): | 49.91% |
Stock Insider Trading Activity of Tarsus Pharmaceuticals Inc. (TARS)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Azamian Bobak R. | TARS | President/CEO and Board Chair | Sep 24 '25 | Sell | $55.37 | 6,000 | $332,220.00 | 812,106 | |
| LINK WILLIAM J PHD | TARS | Director | Sep 8 '25 | Sell | $57.00 | 27,116 | $1,545,612.00 | 143,332 | |
| Azamian Bobak R. | TARS | President/CEO and Board Chair | Aug 11 '25 | Sell | $50.00 | 6,000 | $300,000.00 | 812,106 |
Latest Tarsus Pharmaceuticals Inc. News
TARS Breaking Stock News: Dive into TARS Ticker-Specific Updates for Smart Investing
Zacks
23 days ago
Tarsus Pharmaceuticals (TARS) Moves 10.9% Higher: Will This Strength Last?
MT Newswires
4 months ago
Tarsus Pharmaceuticals Insider Sold Shares Worth $550,035, According to a Recent SEC Filing
MT Newswires
5 months ago
Oppenheimer Adjusts Price Target on Tarsus Pharmaceuticals to $75 From $72, Maintains Outperform Rating
GlobeNewswire
5 months ago
Tarsus to Participate in Upcoming Investor Conferences
Zacks
5 months ago
Tarsus Pharmaceuticals (TARS) Loses -15.59% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
GlobeNewswire
6 months ago
Tarsus to Participate in Upcoming Investor Conferences
Insider Monkey
6 months ago
Tarsus Pharmaceuticals, Inc. (TARS): Among the Best Breakout Stocks to Buy According to Analysts
Simply Wall St.
6 months ago
Analysts Just Made A Substantial Upgrade To Their Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Forecasts
Compare TARS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TARS Tarsus Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.